NCT03393325View on ClinicalTrials.gov

Tadalafil-Delivra and Raynaud's Phenomenon

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

October 31, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

September 30, 2019

Conditions
Raynaud Phenomenon
Interventions
OTHER

Observation of treatment with Tadalafil-Delivra

Tadalafil 2% in a Delivra base (Transdermal Application)

Trial Locations (2)

L8N 4A6

St. Joseph's Healthcare, Hamilton

M5T3L9

Mount Sinai Hospital, Toronto

Sponsors

Collaborators (1)

Delivra, Inc.
All Listed Sponsors
collaborator

Delivra, Inc.

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER